Biohaven (BHVN) Expected to Announce Quarterly Earnings on Monday

Key Points

• Biohaven is expected to report Q3 2026 earnings after the market closes on Monday, November 9. Analysts anticipate a loss of $0.7833 per share and revenue of approximately $63.64 million.
• The company previously reported a larger-than-expected Q2 loss of $0.91 per share versus the $0.76 consensus estimate. Analysts project full-year and next-year losses of $3.03 and $2.63 per share, respectively.
• Biohaven shares opened at $15.76, near the upper half of their $7.48–$18.24 12-month range. Analyst sentiment is a consensus “Moderate Buy,” with an average price target of $19.94, although ratings range from “Strong Buy” to “Sell.”

Biohaven (NYSE:BHVN - Get Free Report) is projected to post its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Biohaven to announce earnings of ($0.7833) per share and revenue of $63.64 million for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 7:00 AM ET.

Biohaven (NYSE:BHVN - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, analysts expect Biohaven to post ($3.03) EPS for the current fiscal year and ($2.63) EPS for the next fiscal year.

Biohaven Stock Performance

Shares of BHVN opened at $15.76 on Monday. The stock has a 50-day moving average price of $13.63 and a 200-day moving average price of $12.24. The company has a market cap of $2.38 billion, a PE ratio of -4.08 and a beta of 1.35. Biohaven has a 12-month low of $7.48 and a 12-month high of $18.24. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 21.23.

Analyst Upgrades and Downgrades

BHVN has been the topic of a number of recent analyst reports. Canaccord Genuity Group lifted their price objective on Biohaven from $21.00 to $32.00 and gave the stock a "buy" rating in a research report on Friday. Weiss Ratings reiterated a "sell (e+)" rating on shares of Biohaven in a research note on Friday, August 28th. Robert W. Baird set a $48.00 price objective on shares of Biohaven in a research report on Thursday, October 22nd. Raymond James Financial reaffirmed a "strong-buy" rating on shares of Biohaven in a report on Thursday, October 8th. Finally, Citigroup reissued a "buy" rating on shares of Biohaven in a research note on Friday, September 18th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $19.94.

About Biohaven

Biohaven Ltd. NYSE: BHVN is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company's research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven's pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.